# Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma

> **NCT06806579** · — · RECRUITING · sponsor: **IRCCS Azienda Ospedaliero-Universitaria di Bologna** · enrollment: 1000 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06806579
- **Lead sponsor:** IRCCS Azienda Ospedaliero-Universitaria di Bologna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-21
- **Primary completion:** 2030-10-31
- **Final completion:** 2031-10-31
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06806579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06806579, "Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06806579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*